Armando OrlandiΒ· @ArmandOrlandi Β· XΒ·Β· 2 days agoScore70
Body Β· original
Cowabunga! π Riding the Breast Cancer Wave ππ»ββοΈπ€π» from #ESMO26
TALENT: neoadjuvant trastuzumab deruxtecan in luminal HER2-low tumors.β¨
Residual Cancer Burden 0/1: 16β17%.
Tumors shrink, rarely disappear.
Wrong endpoint or wrong combination?
@OncoAlert
@Larvol
309 views Β· 4 likes Β· 5 reposts Β· 0 replies
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgSource: Armando Orlandi Β· x.com